Tag: Patients

The International Polycap Study 3 (TIPS-3) was conducted in 89 centres from nine countries, including 39 centres in India. The study took about 8 years to complete globally with participants taking medication for an average of 4.5 years............

ILUMYA is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials in moderate-to-severe plaque psoriasis.......................

Access to enzyme replacement therapy big challenge for Gaucher patients. Covid-19 has brought with it little to no access to hospitals for patients suffering from Gaucher......................

The patients have moved to therapy on demand to avoid going to hospitals due to the pandemic. Access to factor replacement therapy, regular monitoring and physiotherapy, helps children and adults lead productive lives...................

India has reported the highest number of total recoveries with more than 42 lakh (42,08,431) COVID patients recovered and discharged.....................

The union government has made the States and Union Territories responsible for ensuring that every hospitalized COVID-19 patient receives oxygen..............

New research found physicians and patients agree that there are widening gaps in vascular disease treatment. 55% of physicians from nine countries around the globe, including India, say the shortage of time to spend with each patient is the biggest challenge to improving the patient experience and delivering better outcomes.................

According to OMRON Healthcare India, the global leader in digital blood pressure home monitoring devices, more number of Indians are buying Digital Blood Pressure Monitors (BPMs) to monitor their vital parameters effectively.......................

IIT Madras’ Healthcare Technology Innovation Centre (HTIC) and Helyxon, a healthcare startup in IIT Madras Research Park have announced the successful deployment of remote patient monitoring solutions for COVID-19 that they have jointly developed...............

Sun Pharma has launched FluGuard® (Favipiravir 200 mg) at a comparatively economical price of Rs 35 per tablet, for the treatment of mild to moderate cases of Covid-19 in India...............